TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16735174

Group type: COMPARATOR
Intervention: Metabolite ratio (citrate/(choline+creatine)) and ADC values in patients with PSA >20 ng/ml (Group II)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metabolite ratio and ADC values in patients with PSA 4-20 ng/ml (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) imaging
Number of subjects: 40

Group type: COMPARATOR
Intervention: TRUS-guided biopsy
Number of subjects: 40
Study: 14585635

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 41
Study: 15277588

Group type: EXPERIMENTAL
Intervention: Adapted Project Northland intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10466240

Group type: EXPERIMENTAL
Intervention: Adjuvant RT started within 4 weeks after breast surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant RT started after a delay of up to 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous tissue transfer for breast reconstruction after mastectomy and adjuvant RT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate reconstruction before RT or delayed reconstruction after RT using TRAM procedure
Number of subjects: 0
Study: 8626878

Group type: EXPERIMENTAL
Intervention: Low-dose amlodipine 2.5 mg daily
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Low-dose benazepril 10 mg daily
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine 2.5 mg and benazepril 10 mg daily
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Amlodipine and benazepril regimen
Number of subjects: 401
Study: 2399132

Group type: EXPERIMENTAL
Intervention: Extremity wraps
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no extremity wraps)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shivering
Number of subjects: 40
Study: 120078

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 30642308

Group type: EXPERIMENTAL
Intervention: Early medication change (EMC) strategy with immediate switch to high doses of venlafaxine XR
Number of subjects: 192

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with continued escitalopram until day 28
Number of subjects: 192

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 192
Study: 28545804

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 50 µg once daily in the evening
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 50 µg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 60
Study: 25884803

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management (TCM) programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Teach as normal (control)
Number of subjects: 80
Study: 23712210

Group type: EXPERIMENTAL
Intervention: CBT-ERT (Cognitive Behavioral Therapy enriched with Emotion Regulation Training)
Number of subjects: 432

Group type: COMPARATOR
Intervention: CBT (Cognitive Behavioral Therapy)
Number of subjects: 432
Study: 19616860

Group type: EXPERIMENTAL
Intervention: Fast-tracked group in a community scheme led by an exercise instructor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Phase III hospital group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phase IV attendees
Number of subjects: 100
Study: 18955525

Group type: EXPERIMENTAL
Intervention: OPT-80 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OPT-80 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OPT-80 200 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: OPT-80 (all dosages)
Number of subjects: 48
Study: 17175106

Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 98

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD-Ag)
Number of subjects: 98
Study: 15033398

Group type: EXPERIMENTAL
Intervention: Size 70 diaphragm without clinician fitting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm-based fitting (considering parity, body weight, etc.)
Number of subjects: 0
Study: 11320586

Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study: 9272758

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8174716

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) plus oral contraceptive (OC) containing cyproterone acetate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) alone
Number of subjects: 32
Study: 29283797

Group type: EXPERIMENTAL
Intervention: Subjective sleep assessments (questionnaire)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Objective sleep assessments (actigraphy)
Number of subjects: 59
Study: 27087213

Group type: EXPERIMENTAL
Intervention: Sunshine exposure on weekdays
Number of subjects: 43771

Group type: EXPERIMENTAL
Intervention: Sunshine exposure on weekends
Number of subjects: 43771

Group type: COMPARATOR
Intervention: Factors influencing sunshine exposure on weekdays
Number of subjects: 43771

Group type: COMPARATOR
Intervention: Factors influencing sunshine exposure on weekends
Number of subjects: 43771

Group type: COMPARATOR
Intervention: Multivariate logistic regression analysis
Number of subjects: 43771
Study: 25712537

Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate/17β‐estradiol (NOMAC/E2)
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Drospirenone/ethinylestradiol (DRSP/EE)
Number of subjects: 3522
Study: 22925421

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 106

Group type: COMPARATOR
Intervention: normal saline 0.9% (NS)
Number of subjects: 106
Study: 20627691

Group type: EXPERIMENTAL
Intervention: Ethyl chloride (cold)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibrated Neuropen (sharp)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized monofilament 10 g (pressure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurotip stroking (light touch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monofilament stroking (light touch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotton wool (light touch)
Number of subjects: 0
Study: 18692890

Group type: EXPERIMENTAL
Intervention: Predicate metaphors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Literal sentences
Number of subjects: 0
Study: 16723364

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Ofloxacin plus metronidazole (ofloxacin 400 mg twice daily + metronidazole 500 mg twice daily)
Number of subjects: 741
Study: 12729115

Group type: EXPERIMENTAL
Intervention: PCL-retained total knee replacement
Number of subjects: 129

Group type: COMPARATOR
Intervention: PCL-resected total knee replacement
Number of subjects: 129
Study: 11049904

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 500

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 500

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 500
Study: 8971305

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (patients remaining H. pylori-positive)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patients cured of H. pylori infection
Number of subjects: 121
Study: 1595789

Group type: EXPERIMENTAL
Intervention: Buserelin acetate (400 micrograms intranasal three times daily for 6 months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Buserelin acetate
Number of subjects: 71
Study: 2996310

Group type: EXPERIMENTAL
Intervention: Lipid lowering diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (high vs low cholesterol reduction)
Number of subjects: 16
Study: 30346481

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg orally twice daily for ≤3 years (minimum 1 year unless recurrence, second primary malignancy, significant toxicity, or consent withdrawal)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 25765462

Group type: EXPERIMENTAL
Intervention: Mesalazine 2 g twice daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 136
Study: 24991045

Group type: EXPERIMENTAL
Intervention: Buttermilk drink containing 1.5 lutein-rich egg yolks daily for 1 year
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers consuming the lutein-enriched drink
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cholesterol absorbers, cholesterol synthesizers, and average campesterol-to-lathosterol ratio participants
Number of subjects: 101
Study: 22271239

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Attendant presence
Number of subjects: 120
Study: 19692186

Group type: EXPERIMENTAL
Intervention: Iron reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 18384442

Group type: EXPERIMENTAL
Intervention: Budesonide (1000-mug dose via dry powder inhaler)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1000-mug dose via dry powder inhaler)
Number of subjects: 22
Study: 15938587

Group type: EXPERIMENTAL
Intervention: DermaVite (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 11902619

Group type: EXPERIMENTAL
Intervention: Actions taken after positive or absent prior outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactions following negative prior outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differential effects for regret and disappointment in Experiment 4
Number of subjects: 0
Study: 9915317

Group type: EXPERIMENTAL
Intervention: Target effect compartment concentration of propofol (5.4 microg/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Target central compartment concentration of propofol (5.4 microg/ml)
Number of subjects: 20
Study: 7752177

Group type: EXPERIMENTAL
Intervention: High-salt diet (14 patients) switched to low-salt diet for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-salt diet (16 patients) switched to high-salt diet for 4 weeks
Number of subjects: 30
Study: 2261927

Group type: EXPERIMENTAL
Intervention: Direct-vision endoscopic urethrotomy (cold-knife incision at 12 o'clock)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Internal urethrotomy plus Nd‐YAG laser
Number of subjects: 30
Study: 7005134

Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg, two days a week, for eight weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31266489

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 15.6 μg twice daily
Number of subjects: 867

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study: 29724638

Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 9.1 mg
Number of subjects: 357

Group type: COMPARATOR
Intervention: Intramuscular aripiprazole 9.75 mg
Number of subjects: 357
Study: 27082959

Group type: EXPERIMENTAL
Intervention: TAP infiltration with liposomal bupivacaine
Number of subjects: 318

Group type: COMPARATOR
Intervention: Continuous Epidural analgesia with plain bupivacaine
Number of subjects: 318

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 318
Study: 25068233

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy (20-30 mg/day) for 6 months associated with dietary supplement (twice a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Isotretinoin therapy (20-30 mg/day) for 6 months
Number of subjects: 48
Study: 22193433

Group type: EXPERIMENTAL
Intervention: 200 U BTX‐A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 U BTX‐A
Number of subjects: 20
Study: 20645486

Group type: EXPERIMENTAL
Intervention: remifentanil, propofol, and sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: remifentanil, propofol, and rocuronium
Number of subjects: 100
Study: 18336921

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes (TT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15978972

Group type: COMPARATOR
Intervention: Raloxifene 120 mg/day
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg/day
Number of subjects: 37
Study: 12544981

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 0
Study: 10569171

Group type: EXPERIMENTAL
Intervention: Barrier Ophthalmology Drape (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Steri Drape 1062 (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cotton drape + Steri Drape 1024 (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 60
Study: 9213879

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride (100 mg twice a day for 10 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (non-steroidal anti-inflammatory drugs for rheumatoid arthritis, paracetamol for OA and vertebrogen syndrome)
Number of subjects: 68
Study: 1927946

Group type: EXPERIMENTAL
Intervention: Soluble aspirin, 100 mg/day
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 6350247

Group type: EXPERIMENTAL
Intervention: Carbohydrate feeding (glucose polymer solution)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31557585

Group type: COMPARATOR
Intervention: Home exercises (HOME)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation (REHAB)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups (HOME and REHAB)
Number of subjects: 146
Study: 30782714

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 0
Study: 27461092

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (animated short films)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 40
Study: 25029557

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Isotonic solution (Gatorade®)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no hydration)
Number of subjects: 31
Study: 23629739

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring without nurse support
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Monitoring weekly after 1 month
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no monitor offered)
Number of subjects: 237
Study: 22210421

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 19808309

Group type: EXPERIMENTAL
Intervention: HeartMate I LVAD implantation at centers performing <=4 DT implants
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: HeartMate I LVAD implantation at centers performing >9 DT implants
Number of subjects: 377
Study: 17693215

Group type: EXPERIMENTAL
Intervention: 8-week RAS music-movement exercise intervention (n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Referral information about available usual care services (n = 17)
Number of subjects: 33
Study: 15155328

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg succinylcholine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg succinylcholine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 115
Study: 10986213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 39
Study: 8841892

Group type: EXPERIMENTAL
Intervention: HTR (Hard Tissue Replacement Synthetic Bone)
Number of subjects: 1

Group type: COMPARATOR
Intervention: FDBA (freeze-dried bone allograft)
Number of subjects: 1
Study: 1994867

Group type: EXPERIMENTAL
Intervention: Stanozolol treatment in primary Raynaud's phenomenon
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stanozolol treatment in systemic sclerosis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 43
Study: 6500169

Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg of body-weight)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aspirin (15 mg/kg of body-weight)
Number of subjects: 28
Study: 31508504

Group type: EXPERIMENTAL
Intervention: Bradoriids with varying limb morphologies and limb-tagmosis patterns
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Monophyletic stem-euarthropod group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alternative solution of polyphyletic bradoriids
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Evolutionary convergence
Number of subjects: 3
Study: 29886423

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Nifedipine slow release 30 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Telmisartan/Nifedipine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High altitude exposure
Number of subjects: 55
Study: 1463157

Group type: EXPERIMENTAL
Intervention: 0.06 to 0.08 mg intrathecal morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without morphine
Number of subjects: 30
Study: 22721546

Group type: EXPERIMENTAL
Intervention: Adherence to medication
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Non-adherence to medication
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 140
Study: 21702271

Group type: EXPERIMENTAL
Intervention: Ambulatory cleft lip surgery under loco-regional anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inpatient cleft lip surgery under general anaesthesia
Number of subjects: 80
Study: 18766096

Group type: EXPERIMENTAL
Intervention: Hypercapnic condition (7% CO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normocapnic condition (5% CO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypocapnic condition (2% CO2)
Number of subjects: 20
Study: 15974833

Group type: EXPERIMENTAL
Intervention: PON1 192 AA and PON1 55 MM genotypes
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PON1 192 BB and PON1 55 LL genotypes
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PON1 192 BB and PON1 55 LL alleles
Number of subjects: 213
Study: 12683740

Group type: EXPERIMENTAL
Intervention: UV photo intervention
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: UV photo information
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination of UV photo and photoaging information
Number of subjects: 144
Study: 10222548

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg qPM
Number of subjects: 74

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 74
Study: 8927743

Group type: EXPERIMENTAL
Intervention: Smoking 1-20 cigarettes per day
Number of subjects: 551

Group type: COMPARATOR
Intervention: Nonsmoking females
Number of subjects: 551
Study: 2064494

Group type: COMPARATOR
Intervention: Nutritional-hygienic intervention alone (placebo)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention plus antihypertensive medication (diuretic, beta-blocker, alpha 1-antagonist, calcium antagonist, or ACE inhibitor)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention
Number of subjects: 902
Study: 6242795

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous intravenous insulin infusion (CIVII)
Number of subjects: 6
Study: 31087588

Group type: EXPERIMENTAL
Intervention: Nature soundscapes (easy to recognize)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nature soundscapes (hard to recognize)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urban soundscapes (hard to recognize)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-generated artificial noises (similar properties to nature and urban sounds)
Number of subjects: 0
Study: 30545918

Group type: EXPERIMENTAL
Intervention: Network switching
Number of subjects: 1003
Study: 27300086

Group type: EXPERIMENTAL
Intervention: Neonatal face-to-face interactions with human caregivers (mutual gaze and intermittent lip-smacking)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Additional handling (control group)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Neonatal face-to-face interactions with mothers
Number of subjects: 2
Study: 25323890

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets
Number of subjects: 62

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 62
Study: 20734057

Group type: EXPERIMENTAL
Intervention: Isotopically labeled water
Number of subjects: 200